Related Experiment Videos
Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study
J Morote Robles1, A Ruibal Morell, J Palou Redorta
1Service of Urology, C.S. Vall d'Hebron, Barcelona, Spain.
European Urology
|January 1, 1988
Summary
Prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) serum levels were measured in 1,383 patients. PSA demonstrated higher sensitivity and clinical efficacy for detecting prostate cancer compared to PAP.
Area of Science:
- Urology
- Oncology
- Clinical Chemistry
Background:
- Prostate cancer diagnosis relies on tumor markers.
- Prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) are key serum markers.
- Accurate assessment of these markers is crucial for patient management.
Purpose of the Study:
- To evaluate the diagnostic accuracy of PSA and PAP serum levels.
- To compare the clinical efficacy of PSA and PAP in patients with prostate conditions.
- To establish normal limits and assess false positive rates.
Main Methods:
- Radioimmunoassay (RIA) using 125I was employed.
- Serum levels of PSA and PAP were assayed in 1,383 patients.
- Upper normal limits were set at 10 ng/ml for PSA and 2.5 ng/ml for PAP.
Main Results:
- PSA showed higher sensitivity (87.2%) than PAP (64.1%) in prostate cancer patients.
- PSA correlated better with tumor spread and histologic grading.
- Clinical efficacy was superior for PSA, with no added benefit from combined testing.
Conclusions:
- PSA is a more effective tumor marker than PAP for prostate cancer.
- PSA offers superior diagnostic accuracy and prognostic correlation.
- Combined testing of PSA and PAP does not enhance clinical utility.